Clinical trial NCT05671757: Daratumumab in Primary Antiphospholipid Syndrome
Official title: Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Autoimmune Disorders
Keywords: Daratumumab
Anti-Phospholipid Syndrome
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
Collaborators: name: Immune Tolerance Network (ITN)
name: PPD Development, LP
name: Rho Federal Systems Division, Inc.
First posted: 2023-01-05
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS).

Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab according to the following schedule, for a total of 8 doses.

The primary objective is to determine the safety of daratumumab in APS defined as Dose Limiting Toxicities (DLTs) occurring during the dose escalation phase.

Detailed description: The trial is a phase 1b open-label study of daratumumab in participants with APS.

The study design is a modification of the 3 + 3 dose escalation scheme. Three daratumumab dose cohorts are planned: 4 mg/kg, 8 mg/kg, and 16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48.

Dose Escalation Phase Dose escalation will proceed according to safety criteria (Dose Limiting Toxicity, DLT) and efficacy criteria (antiphospholipid antibody negativity). An independent safety committee will review the data and approve escalation to the next dose.

The Highest Safe Dose (HSD) is the highest administered dose at which ≤ 1/6 participants experiences a DLT at or prior to week 9.

Expansion Phase Four additional participants will be enrolled and treated at the HSD weekly for 8 doses.

Eligibility criteria: Inclusion Criteria:

1. Adults 18 to 70 years of age, inclusive.
2. The completion of the following vaccinations at least 14 days prior to Visit 0:

   1. At least one dose of the most recently updated COVID-19 vaccine, and
   2. At least one dose of the herpes zoster vaccination series, and
   3. Current seasonal influenza vaccine, if available.
3. History of APS according to the updated 2006 Sapporo classification criteria, including at least one of the following:

   a. Arterial thrombosis, except transient ischemic attack, confirmed by objective validated criteria such as imaging, or b. Venous thrombosis, except superficial thrombophlebitis, confirmed by objective validated criteria such as imaging, or c. Pregnancy morbidity, based on the updated 2006 Sapporo APS classification criteria, or d. Microvascular APS, with at least one of the following: i. Renal biopsy documentation of aPL-associated nephropathy, or ii. Lung biopsy or bronchoalveolar lavage documentation of diffuse alveolar hemorrhage (DAH), or iii. Skin biopsy documentation of livedoid vasculopathy.
4. History of triple positive aPL within the prior 5 years and at least 12 weeks prior to enrollment, including all of the following:

   1. aCL IgG level \> Upper Limit of Normal (ULN), and
   2. aβ2GPI IgG level \> ULN, and
   3. Positive LA test.
5. Confirmation of triple positive aPL at screening, including all of the following:

   1. aCL IgG level ≥ 40 GPL, and
   2. aβ2GPI IgG level ≥ 40 SGU, and
   3. Positive LA test.
6. Undergoing anticoagulation with warfarin or low molecular weight heparin (LMWH), if there is a history of arterial or venous thrombosis.

Exclusion Criteria:

1. Inability or unwillingness to give written informed consent.
2. Inability or unwillingness to comply with study protocol.
3. Systemic autoimmune diseases other than APS, including but not limited to:

   1. Systemic lupus erythematosus (SLE) meeting the EULAR/ACR classification criteria.
   2. Rheumatoid arthritis meeting the ACR/EULAR classification criteria.
   3. Small, medium, and large vessel vasculitis meeting ACR classification criteria.
4. Catastrophic APS classification within the prior 90 days.
5. Acute arterial or venous thrombosis within the prior 30 days.
6. Use of the following medications:

   1. Any prior treatment with CD38 targeting monoclonal antibodies, including daratumumab or isatuximab-irfc.
   2. Administration of the Janssen COVID-19 vaccine within the prior 14 days.
   3. The following within the prior 30 days:

   i. Corticosteroids \> 10 mg/day prednisone or equivalent. ii. Direct oral anticoagulants (DOACs). iii. Live attenuated vaccines. iv. IVIG or other supplemental immunoglobulin. d. Azathioprine, methotrexate, mycophenolate mofetil, mycophenolate sodium, lefluonomide, or calcineurin inhibitors within the prior 90 days.

   e. Cyclophosphamide within the prior 90 days. f. Immunomodulatory or immunosuppressive biologic agents, including belimumab, within the prior 90 days or 5 half-lives, whichever is greater.

   g. Investigational agents within the prior 90 days or 5 half-lives, whichever is greater, except for COVID-19 vaccines and medications for prevention or treatment of COVID-19 per FDA Emergency Use Authorization (EUA).

   h. Biologic B cell depleting agents including rituximab with any of the following: i. Treatment within the prior 180 days, or ii. CD19+ absolute count \< 40/ μl, or iii. Serum IgG \<500 mg/dL.
7. Plasma exchange within the prior 90 days.
8. Hemodialysis within the prior 90 days.
9. Major surgical procedure within the prior 60 days.
10. Known allergy, hypersensitivity, or intolerance to boron, malitol, sorbitol, corticosteroids, monoclonal antibodies including daratumumab, human proteins, or their excipients.
11. Allergy, intolerance, or contraindication to acyclovir, valacyclovir, and famciclovir.
12. Active or chronic infection, including the following:

    1. Active bacterial, viral, fungal, or opportunistic infection.
    2. Chronic infection requiring suppressive antibiotic treatment.
    3. Intravenous antibiotics or hospitalization for infection within the prior 30 days.
    4. Evidence of current or prior Mycobacterium tuberculosis infection.
    5. Human immunodeficiency virus (HIV).
    6. Current or prior infection with hepatitis B virus (HBV).
    7. Current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response ≥ 12 weeks.
    8. History of recurrent herpes zoster, or history of herpes zoster ophthalmicus, disseminated herpes zoster, or disseminated herpes simplex.
13. The following laboratory abnormalities:

    ITN093AI: DARE-APS Version 3.0 September 12, 2023 Daratumumab in Primary Antiphospholipid Syndrome
    1. Absolute neutrophil count \< 1500/mm3.
    2. Platelets \< 100,000/mm3.
    3. Hemoglobin (Hgb) \< 10 g/dL.
    4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase \> 2x the Upper Limit of Normal (ULN).
    5. Total bilirubin \> 2x ULN, except in the case of congenital bilirubinemia then direct bilirubin \> 2x ULN.
    6. eGFR \< 45 ml/min/1.73 m2.
14. History of primary immunodeficiency.
15. History of solid organ or hematopoietic stem cell transplantation.
16. Comorbidities requiring systemic corticosteroid therapy, including those which have required three or more courses of systemic corticosteroids within the 12 months prior to Visit 0.
17. Any of the following conditions with FEV1 \< 70% predicted within the prior 90 days:

    1. Asthma.
    2. Chronic obstructive pulmonary disease (COPD).
    3. DAH.
18. Pulmonary hypertension.
19. Adrenal insufficiency.
20. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 8.0%.
21. Concomitant malignancy or history of malignancy, except adequately treated or excised nonmetastatic squamous cell carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.
22. Clinically significant cardiac disease, including but not limited to:

    1. Myocardial infarction within the prior 6 months, or
    2. Unstable or uncontrolled disease or condition related to or affecting cardiac function, including but not limited to:

    i. Unstable angina, or ii. Congestive heart failure, New York Heart Association Class II-IV, or iii. Uncontrolled cardiac arrhythmia.
23. Current diagnosed mental illness or current diagnosed or self-reported drug or alcohol abuse which, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
24. Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease.
25. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or may impact the quality or interpretation of the data obtained from the study.
26. Lack of peripheral venous access.
27. Pregnancy, or planning a pregnancy during the 48 week study duration.
28. Breast-feeding.
29. Unwillingness to use medically acceptable non-prothrombotic contraception if of reproductive potential and engaging in sexual activity that could lead to pregnancy.

Primary outcomes:
measure: The proportion of participants in the dose escalation phase with at least one Dose Limiting Toxicity (DLT)
timeFrame: At or before week 9
Secondary outcomes:
measure: The proportion of participants with the following Grade 3 or higher adverse events (AEs) related to daratumumab
timeFrame: At or before weeks 9, 24, and 48.
measure: The proportion of Grade 2 or higher adverse event (AEs) related to daratumumab
timeFrame: At or before weeks 9, 24, and 48
measure: The proportion of participants with negative Lupus Anticoagulant (LA) test
timeFrame: At week 9
measure: The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG)
timeFrame: At week 9 compared to week 0
measure: The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels
timeFrame: At week 9 compared to week 0
measure: The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels
timeFrame: At week 24 compared to week 0
measure: The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels
timeFrame: At week 48 compared to week 0
measure: The proportion of participants with a negative Lupus Anticoagulant (LA) test
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: The proportion of participants with a negative Lupus Anticoagulant (LA) test
timeFrame: At week 24
measure: Change in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels
timeFrame: From weeks 0 to weeks 4, 9, 12, 18, 24, 36 and 48
measure: Change in Anticardiolipin antibodies Immunoglobulin M (aCL IgM) levels
timeFrame: From week 0 to weeks 4, 9, 12, 18, 24, 36 and 48
measure: The proportion of Grade 2 or higher serious adverse event (SAEs) related to daratumumab
timeFrame: At or before weeks 9, 24, and 48
measure: The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein I antibodies (a-beta2GPI IgG) compared to week 0
timeFrame: At week 9
measure: The proportion of participants with a negative Lupus Anticoagulant (LA) test
timeFrame: At week 48
measure: The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels
timeFrame: At week 48 compared to week 0
Other outcomes:
measure: MECHANISTIC: The frequency specific immune cell populations in viably cryopreserved Peripheral Blood Mononuclear Cell (PBMC)
timeFrame: At weeks 4, 9, 17, 25, 36 and 48
measure: MECHANISTIC:The functional status of specific immune cell populations in viably cryopreserved Peripheral Blood Mononuclear Cell (PBMC)
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: Immunophenotypin
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: Level of circulating cell
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: The effect of treatment dose on specific cell phenotypes
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: The effect of treatment dose on specific cell profiles
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: Levels of soluble immune mediators
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: Levels of soluble immune antibodies
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
measure: MECHANISTIC: Global changes in gene expression of molecules
timeFrame: At weeks 4, 9, 12, 18, 24, 36 and 48
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
city: Great Neck
country: United States
facility: Northwell Health
state: New York
city: New York
country: United States
facility: NYU Langone
state: New York
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
city: New York
country: United States
facility: Weill Cornell
state: New York
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Hospital for Special Surgery, New York: Division of Rheumatology
name: Doruk Erkan, M.D., M.P.H.
role: STUDY_CHAIR
affiliation: University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
name: Jason Knight, M.D., Ph.D.
role: STUDY_CHAIR
References: